Randomized Comparison of the Safety and Efficacy of Tazarotene 0.1% Cream andAdapalene 0.3% Gel in the Treatment of Patients With at Least Moderate FacialAcne Vulgaris
May 2010 | Volume 9 | Issue 5 | Original Article | 549 | Copyright © May 2010
Emil Tanghetti MD, Sunil Dhawan MD, Lawrence Green MD, James Del Rosso DO, Zoe Draelos MD,James Leyden MD, Alan Shalita MD, Dee Anna Glaser MD, Pearl Grimes MD, Guy Webster MD PhD,Pamela Barnett BS, Nicolas Le Gall MSc
This 16-week study evaluated once-daily tazarotene 0.1% cream and adapalene 0.3% gel in patients with moderate-to-severe acne.
Patients treated with tazarotene 0.1% cream performed better in many acne efficacy measures (reduction in lesion counts, percentage
of patients achieving a 50 percent lesion count reduction, overall disease severity, investigator’s global assessment) than did
patients treated with adapalene 0.3% gel. Reduction in postinflammatory hyperpigmentation (PIH) was also significantly greater with
tazarotene 0.1% cream than with adapalene 0.3% gel (P≤0.018). Irritation was infrequent, generally mild and similar between treatment
groups. In conclusion, both tazarotene 0.1% cream and adapalene 0.3% gel were effective and well tolerated in patients with
at least moderate acne. Tazarotene 0.1% cream appeared to be more effective and nearly as well tolerated as adapalene 0.3% gel
in reducing acne lesions and was more effective than adapalene 0.3% gel in reducing PIH.